- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Ketamine Treatment
Recent news which mentions Ketamine Treatment
From Benzinga
Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
January 08, 2024
From Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
From Benzinga
Super Model Chrissy Teigen Talks About Ketamine Therapy Session, Says She Saw 'Space & Time'
December 04, 2023
From Benzinga
Defense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & Veterans
November 27, 2023
From Benzinga
Johnson & Johnson's Q3 2023: $21.3B Rise In Sales, 'Sharpened Focus' On Innovation & Biotech Solutions
October 17, 2023
Tickers
JNJ
From Benzinga
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
October 16, 2023
From Benzinga
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
September 06, 2023
Tickers
PHRRF
From Benzinga
Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based Treatment
August 08, 2023
Tickers
SILO
From Benzinga
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
June 27, 2023
From Benzinga
From Benzinga
Seelos Therapeutics Positive Q1 Financials Make For 'The Most Important Year' In Company's History
May 16, 2023
Tickers
SEEL
From Benzinga
Atai Advances R-Ketamine Through Phase 1 Bridging Study, Update And Near-Term Expectations
April 14, 2023
Tickers
ATAI
From Benzinga
Ketamine Company Advances Parkinson's Treatment Through Final Stages Toward FDA Approval
March 30, 2023
Tickers
PHRRF
From Benzinga
Breakthrough Treatment For PTSD? This Ketamine Cream Showing Promise In Alleviating Symptoms
March 22, 2023
Tickers
BWVI
From Benzinga
From Benzinga
Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
February 22, 2023
Tickers
AWKNF
From Benzinga
Novel Ketamine Topical Cream To Treat PTSD Gets First In-Human Trials
February 16, 2023
Tickers
BWVI
From Benzinga
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
February 14, 2023
From Benzinga
Seelos Dosing Participants In Psychedelics Study, Seeks Japanese Subjects In Major Depression Therapy
February 07, 2023
Tickers
SEEL
From Benzinga
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
February 03, 2023
From Benzinga
Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results
January 31, 2023
Tickers
CMND
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.